MDMA-assisted dialectical behavioral therapy for borderline personality disorder: A qualitative study of mental health clinicians
Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower
Journal of Psychedelic Studies February 5, 2024 DOI: 10.1556/2054.2023.00281 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 4 |
| Population | Clinicians (two dialectical behavioral therapy clinicians and two MDMA-assisted therapy clinicians) |
| Topics | MDMA |
| Keywords | Borderline personality disorder Dialectical behavior therapy Behavioral therapy Mental health Psychotherapist Clinical psychology |
| Citations | 1 |
| Key findings | Clinicians' perspectives revealed a chronological narrative with three phases of treatment for MDMA-assisted therapy in borderline personality disorder. |
Abstract
Abstract In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of the beneficial effects of MDMA-assisted therapy may be applicable in treating BPD. Interviewing two clinicians utilizing dialectical behavioral therapy treatment and two MDMA-assisted therapy clinicians was one way to examine the phenomenology of MDMA-assisted therapy with BPD individuals in a thoughtful manner. An exploratory, qualitative, interview-based study assessed clinicians' perspectives of MDMA-assisted therapy and BPD and increased our understanding of underlying therapeutic mechanisms and processes and the role of pharmacological factors in these treatment modalities, optimizing treatment context, and leading to improved clinical responses and patient recovery. The codes generated unique perspectives of the participants revealing a chronological narrative which included three phases of treatment.
Comparable studies
Other qualitative studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Phenomenology and Sequelae of 3,4-Methylenedioxymethamphetamine Use Psychiatrists who had taken MDMA | 1992 | Qualitative study | n = 20 |
| MDMA and Sexual Behavior: Ecstasy Users' Perceptions About Sexuality and Sexual Risk Current and former users of MDMA | 2005 | Qualitative study | n = 98 |
| Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD Veterans, firefighters, and police officers with chronic, treatment-resistant PTSD | 2019 | Qualitative study using interpretative phenomenological analysis | n = 19 |
| Negative Experiences on Ecstasy: The Role of Drug, Set, and Setting Current or former users of Ecstasy | 2002 | Qualitative study | n = 98 |
| A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing Practitioners who have administered MDMA and psilocybin to clients in underground... | 2021 | Qualitative study | n = 23 |
Citations in the library
Cited by 1
Cites 17
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology July 19, 2010
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology September 1, 2019
and 12 more in the library